Tumour suppression by the human von Hippel-Lindau gene product
- PMID: 7585187
- DOI: 10.1038/nm0895-822
Tumour suppression by the human von Hippel-Lindau gene product
Abstract
A partial cDNA sequence for the gene linked to the von Hippel-Lindau (VHL) syndrome was reported in 1993. Mutation or loss of both VHL alleles has been documented in sporadic renal cell carcinomas and in the neoplasms that arise in von Hippel-Lindau kindreds. We have determined that the protein product of the VHL gene is an approximately 30 kilodalton cytoplasmic protein. The renal carcinoma cell line 786-O is known to harbour a VHL mutation and, as shown here, fails to produce a wild-type VHL protein. Reintroduction of wild-type, but not mutant, VHL into these cells had no demonstrable effect on their growth in vitro but inhibited their ability to form tumours in nude mice.
Similar articles
-
Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein.Mol Cell Biol. 1999 Feb;19(2):1486-97. doi: 10.1128/MCB.19.2.1486. Mol Cell Biol. 1999. PMID: 9891082 Free PMC article.
-
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.Cancer Res. 2002 Jul 1;62(13):3803-11. Cancer Res. 2002. PMID: 12097293
-
Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.Cancer Res. 1996 May 15;56(10):2299-301. Cancer Res. 1996. PMID: 8625303
-
Von Hippel-Lindau disease and sporadic renal cell carcinoma.Cancer Surv. 1995;25:219-32. Cancer Surv. 1995. PMID: 8718521 Review.
-
The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis.Cancer Genet Cytogenet. 1997 Jan;93(1):74-83. doi: 10.1016/s0165-4608(96)00296-8. Cancer Genet Cytogenet. 1997. PMID: 9062583 Review.
Cited by
-
Molecular chaperones: Guardians of tumor suppressor stability and function.Oncotarget. 2024 Oct 1;15:679-696. doi: 10.18632/oncotarget.28653. Oncotarget. 2024. PMID: 39352796 Free PMC article. Review.
-
How oxygenation shapes immune responses: emerging roles for physioxia and pathological hypoxia.Nat Rev Immunol. 2024 Sep 30. doi: 10.1038/s41577-024-01087-5. Online ahead of print. Nat Rev Immunol. 2024. PMID: 39349943 Review.
-
Recent Insights into Roles of Hypoxia-Inducible Factors in Retinal Diseases.Int J Mol Sci. 2024 Sep 21;25(18):10140. doi: 10.3390/ijms251810140. Int J Mol Sci. 2024. PMID: 39337623 Free PMC article. Review.
-
Total loss of VHL gene function impairs neuroendocrine cancer cell fitness due to excessive HIF2α activity.Proc Natl Acad Sci U S A. 2024 Oct;121(40):e2410356121. doi: 10.1073/pnas.2410356121. Epub 2024 Sep 25. Proc Natl Acad Sci U S A. 2024. PMID: 39320914 Free PMC article.
-
VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING.bioRxiv [Preprint]. 2024 Sep 6:2024.09.03.610968. doi: 10.1101/2024.09.03.610968. bioRxiv. 2024. PMID: 39282259 Free PMC article. Preprint.
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
